Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Sponsor

Genentech Inc.

United States 1 Dna Way, 94080-4918, United States

About the sponsor

Genentech Inc. funds a broad oncology portfolio spanning advanced melanoma, non-small cell lung cancer, metastatic breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and advanced prostate cancer. Its studies also include HER2-expressing cancers, KRAS G12C-mutated solid tumors, and other locally advanced or metastatic solid tumors.

  • Advanced melanoma and NRAS-mutant melanoma
  • Breast cancer with ER-positive, HER2-negative disease
  • KRAS-mutant solid tumors and metastatic gastrointestinal cancers
  • B-cell malignancies and multiple myeloma

Research activity also extends to relapsed or refractory multiple myeloma, B-cell malignancies, and other hematologic cancers, alongside solid-tumor programs that target difficult-to-treat metastatic disease.

About Specializations

Genentech Inc. runs clinical trials in conditions such as Breast cancer, Breast cancer metastatic, Hormone receptor positive breast cancer, Colitis ulcerative, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

K-ras gene mutation+1

Recruiting

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Genentech Inc.

Breast cancer+3

Recruiting

A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Genentech Inc.

Colitis ulcerative

Recruiting

Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:RO7837195
  • Sponsor:Genentech Inc.

Glycogen storage disease type II

Recruiting

Study on the Safety and Effects of SPK-3006 for Adults with Late-Onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vanglusagene Ensiparvovec
  • Sponsor:Genentech Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effects of Astegolimab and Drug Combination for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.

Systemic sclerosis pulmonary+1

Not recruiting

Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vixarelimab
  • Sponsor:Genentech Inc.

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Acute kidney injury

Not recruiting

Study of GDC-8264 compared to placebo for preventing kidney injury in patients at risk of acute kidney injury after heart surgery

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7288817
  • Sponsor:Genentech Inc.

Non-small cell lung cancer+1

Not recruiting

Study of Tiragolumab and Atezolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Not Had Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Genentech Inc.

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:Genentech Inc.

Breast cancer+3

Not recruiting

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Genentech Inc.

Chronic lymphocytic leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Genentech Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.